Skip to Main Content

More Transparency Needed for FDA Emergency Authorizations for COVID-19 Products, GAO Says

  • November 20, 2020

The Food and Drug Administration (FDA) should take steps to ensure it discloses consistent information to the public on safety and effectiveness data when issuing emergency use authorizations (EUA) for COVID-19 therapeutics and vaccines, the Government Accountability Office (GAO) advised in a report issued November 17.

You must be logged in to access this content.